141 related articles for article (PubMed ID: 7780691)
1. Cathepsin D in invasive ductal NOS, medullary, lobular and mucinous breast carcinoma. An immunohistochemical study.
Bedner E; Harezga B; Osborn M; Domagała W
Pol J Pathol; 1995; 46(1):11-5. PubMed ID: 7780691
[TBL] [Abstract][Full Text] [Related]
2. Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis.
Jeschke U; Mylonas I; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
Anticancer Res; 2005; 25(3A):1615-22. PubMed ID: 16033070
[TBL] [Abstract][Full Text] [Related]
3. Cysteine proteinase inhibitor cystatin A in breast cancer.
Kuopio T; Kankaanranta A; Jalava P; Kronqvist P; Kotkansalo T; Weber E; Collan Y
Cancer Res; 1998 Feb; 58(3):432-6. PubMed ID: 9458085
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
5. Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas.
Zhang YG; DU J; Tian XX; Zhong YF; Fang WG
Chin Med J (Engl); 2007 Sep; 120(18):1597-605. PubMed ID: 17908479
[TBL] [Abstract][Full Text] [Related]
6. Comparative prognostic value of Cathepsin D and urokinase plasminogen activator, detected by immunohistochemistry, in primary breast carcinoma.
Göhring UJ; Scharl A; Thelen U; Ahr A; Crombach G
Anticancer Res; 1996; 16(2):1011-8. PubMed ID: 8687092
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical visualisation of cathepsin-D expression in breast cancer.
Barthell E; Mylonas I; Shabani N; Kunze S; Kuhn C; Jeschke U; Friese K
Anticancer Res; 2007; 27(4A):2035-9. PubMed ID: 17649818
[TBL] [Abstract][Full Text] [Related]
8. Cathepsin D in invasive ductal NOS breast carcinoma as defined by immunohistochemistry. No correlation with survival at 5 years.
Domagala W; Striker G; Szadowska A; Dukowicz A; Weber K; Osborn M
Am J Pathol; 1992 Nov; 141(5):1003-12. PubMed ID: 1332483
[TBL] [Abstract][Full Text] [Related]
9. Cathepsin-D expression in breast lesion: an immunohistochemical study.
Brujan I; Mărgăritescu C; Simionescu C; Pirici D; Fronie A; Foarfă C; Stepan A; Vrabete M
Rom J Morphol Embryol; 2009; 50(1):31-9. PubMed ID: 19221643
[TBL] [Abstract][Full Text] [Related]
10. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast.
Kominsky SL; Argani P; Korz D; Evron E; Raman V; Garrett E; Rein A; Sauter G; Kallioniemi OP; Sukumar S
Oncogene; 2003 Apr; 22(13):2021-33. PubMed ID: 12673207
[TBL] [Abstract][Full Text] [Related]
11. Cathepsin-D in human breast cancer: correlation with vascular invasion and other clinical and histopathological characteristics.
Hähnel R; Harvey J; Robbins P; Sterrett G
Anticancer Res; 1993; 13(6A):2131-5. PubMed ID: 8297125
[TBL] [Abstract][Full Text] [Related]
12. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
Naidu R; Wahab NA; Yadav MM; Kutty MK
Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618
[TBL] [Abstract][Full Text] [Related]
13. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast.
Brown LF; Guidi AJ; Schnitt SJ; Van De Water L; Iruela-Arispe ML; Yeo TK; Tognazzi K; Dvorak HF
Clin Cancer Res; 1999 May; 5(5):1041-56. PubMed ID: 10353737
[TBL] [Abstract][Full Text] [Related]
14. p53 mutations and histological type of invasive breast carcinoma.
Marchetti A; Buttitta F; Pellegrini S; Campani D; Diella F; Cecchetti D; Callahan R; Bistocchi M
Cancer Res; 1993 Oct; 53(19):4665-9. PubMed ID: 8402644
[TBL] [Abstract][Full Text] [Related]
15. [Cathepsin D expression in primary breast cancer. Comparison of immunohistochemical and biochemical results].
Göhring UJ; Ingenhorst A; Crombach G; Scharl A
Pathologe; 1993 Dec; 14(6):313-7. PubMed ID: 8121884
[TBL] [Abstract][Full Text] [Related]
16. Expression of cathepsin D and galectin 3 in tubular carcinomas of the breast.
Fernandez-Aguilar S; Noël JC
APMIS; 2008 Jan; 116(1):33-40. PubMed ID: 18254778
[TBL] [Abstract][Full Text] [Related]
17. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas.
Moll R; Mitze M; Frixen UH; Birchmeier W
Am J Pathol; 1993 Dec; 143(6):1731-42. PubMed ID: 8256859
[TBL] [Abstract][Full Text] [Related]
18. Cathepsin D immunocytochemical assays in breast carcinomas: image analysis and correlation to prognostic factors.
Charpin C; Devictor B; Bonnier P; Andrac L; Lavaut MN; Allasia C; Piana L
J Pathol; 1993 Aug; 170(4):463-70. PubMed ID: 8410496
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase expression in human breast cancer: an immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2 oncoprotein, p53, steroid receptors status and proliferative indices.
Ioachim EE; Athanassiadou SE; Kamina S; Carassavoglou K; Agnantis NJ
Anticancer Res; 1998; 18(3A):1665-70. PubMed ID: 9673387
[TBL] [Abstract][Full Text] [Related]
20. [Study of G2M cell fraction by flow cytometry in 200 infiltrating ductal breast carcinomas. Correlation with receptor positivity of the epidermal growth factor, cathepsin D and histological grade 3].
Ruibal A; Piqueras V; Núñez MJ; del Río MC; Arias J; Schneider J; Tejerina A
Rev Esp Med Nucl; 1999 Aug; 18(4):312-4. PubMed ID: 10610231
[No Abstract] [Full Text] [Related]
[Next] [New Search]
